The association of C/EBPβ defects with breast cancer progression has been mostly attributed to aberrant levels of LIP isoform that, once elevated, may antagonize the transcriptional activities of LAPs and thus confer a growth advantage to cancer cells (55–58). This evidence concerns the gene CEBPB and breast cancer.